Recent advances in circulating nucleic acids in oncology.

Area of Science:

• Oncology
• Molecular Diagnostics
• Biomarker Discovery

Background:

• Circulating cell-free DNA (cfDNA) is a rapidly advancing field in oncology.
• cfDNA has potential applications across the entire cancer patient management spectrum.
• Recent symposium findings offer new insights into cfDNA's clinical utility.

Purpose of the Study:

• To review recent advances in circulating nucleic acids (DNA/RNA) in oncology.
• To present key findings from the 10th international symposium on circulating nucleic acids.
• To discuss the potential and challenges of implementing cfDNA in clinical oncology.

Main Methods:

• Review of unpublished and initial findings presented at a 2017 symposium.
• Synthesis of recent literature reports on circulating nucleic acids in oncology.
• Focus on specific areas including cfDNA structure, metastatic/immunological roles, miRNA panels, MRD detection, screening, and preanalytical guidelines.

Main Results:

• Advances in understanding cfDNA structure and optimal detection methods.
• Insights into cfDNA's role in metastatic and immunological processes.
• Evaluation of miRNA panels and cfDNA analysis for cancer screening and minimal residual disease (MRD) detection.

Conclusions:

• Circulating nucleic acids, particularly cfDNA, offer significant potential for revolutionizing cancer patient care.
• Further research and standardization are needed for optimal implementation in clinical practice.
• The field is rapidly evolving, with ongoing developments in basic research and clinical application.